Spyre Therapeutics
SYRE
29 hedge funds and large institutions have $43.9M invested in Spyre Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 17 closing their positions.
159% more capital inflows, than outflows
Capital inflows: $17.2M | Capital outflows: $6.63M
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
33% less funds holding
Funds holding: 43 → 29 (-14)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 17
108.4% less ownership
Funds ownership: 108.4% → 0% (-108%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Driehaus Capital Management
Chicago,
Illinois
|
+$8.13M |
| 2 |
Polar Capital Holdings
London,
United Kingdom
|
+$3.97M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.28M |
| 4 |
Logos Global Management
San Francisco,
California
|
+$1.11M |
| 5 |
Perceptive Advisors
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.85M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.54M |
| 3 |
Millennium Management
New York
|
-$797K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$698K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$579K |
SYRE Hedge Fund Activity: Q3 2023 in Review
29 of the 6,317 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2023, worth a combined $43.9M — up 37% from $31.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SYRE and 3 opened new positions — a net loss of 14 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Driehaus Capital Management, adding an estimated $8.13M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.85M sold.
- 29 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2023, down from 43 in Q2 2023.
- Funds reported $43.9M of Spyre Therapeutics stock for Q3 2023, up 37% quarter-over-quarter.
- 3 funds opened new Spyre Therapeutics positions in Q3 2023 and 17 closed out, a net change of -14 holders.
- The largest Spyre Therapeutics buyer in Q3 2023 was Driehaus Capital Management, an estimated $8.13M added.
- The largest Spyre Therapeutics seller in Q3 2023 was Nantahala Capital Management, an estimated $1.85M sold.
Based on aggregated 13F filings for Q3 2023.